
-
US fencer disqualified for not facing transgender rival
-
'Everyone worried' by Trump tariffs in France's champagne region
-
Italy's Brignone suffers broken leg with Winter Olympics looming
-
Iyer blitz powers Kolkata to big IPL win over Hyderabad
-
Russian soprano Netrebko to return to London's Royal Opera House
-
French creche worker gets 25 years for killing baby with drain cleaner
-
UK avoids worst US tariffs post-Brexit, but no celebrations
-
Canada imposing 25% tariff on some US auto imports
-
Ruud wants 'fair share' of Grand Slam revenue for players
-
Lesotho, Africa's 'kingdom in the sky' jolted by Trump
-
Trump's trade math baffles economists
-
Gaza heritage and destruction on display in Paris
-
'Unprecedented crisis' in Africa healthcare: report
-
Pogacar gunning for blood and thunder in Tour of Flanders
-
Macron calls for suspension of investment in US until tariffs clarified
-
Wall St leads rout as world reels from Trump tariffs
-
Mullins gets perfect National boost with remarkable four-timer
-
Trump tariffs hammer global stocks, dollar and oil
-
Authors hold London protest against Meta for 'stealing' work to train AI
-
Tate Modern gifted 'extraordinary' work by US artist Joan Mitchell
-
Mexico president welcomes being left off Trump's new tariffs list
-
Tonali eager to lead Newcastle back into Champions League
-
Lesotho hardest hit as new US tariffs rattle Africa
-
Stellantis pausing some Canada, Mexico production over Trump auto tariffs
-
Rising odds asteroid that briefly threatened Earth will hit Moon
-
Italy reels from Brignone broken leg with Winter Olympics looming
-
Is the Switch 2 worth the price? Reviews are mixed
-
Ancelotti’s tax trial wraps up in Spain with prosecutors seeking jail
-
Civilians act to bring aid to Myanmar earthquake victims
-
US trade gap narrows in February ahead of bulk of Trump tariffs
-
Stocks, dollar and oil sink as gold hits high on Trump tariffs
-
Countries eye trade talks as Trump tariff blitz roils markets
-
Arsenal defender Gabriel out for rest of the season
-
Trump says US to emerge 'stronger' as markets tumble over tariffs
-
Wiegman says Belgium games can aid England's women's Euros title defence
-
Prosecutors demand jail term for Ancelotti for tax fraud
-
Syria accuses Israel of deadly destabilisation campaign
-
Skiing World Cup champion Brignone suffers broken leg
-
Iconic Paris hotel Lutetia taken over by Mandarin Oriental
-
Nepal capital chokes as wildfires rage
-
AI could impact 40 percent of jobs worldwide: UN
-
'Shocking': US tariffs worse than feared for Vietnamese exporters
-
Liverpool's Slot happy to let Premier League title bid take its course
-
USA sole bidder for 2031 Women's World Cup, UK set to host in 2035
-
Tesla sales fall again in Germany amid Musk backlash
-
Italy's skiing champion Brignone air-lifted to hospital after crash
-
US trade partners eye talks after Trump tariff blitz
-
Evenepoel adds Tour de Romandie to comeback programme
-
Defending champion I Am Maximus heads final field for Grand National
-
Rubio says US committed to NATO - but tells allies to spend more
RYCEF | 0.2% | 9.8 | $ | |
RBGPF | -0.41% | 67.72 | $ | |
SCS | -5.62% | 10.85 | $ | |
RIO | -1.93% | 58.765 | $ | |
CMSC | -0.94% | 22.29 | $ | |
GSK | 3.62% | 39.055 | $ | |
BTI | 4.27% | 42.045 | $ | |
AZN | 2.74% | 74.255 | $ | |
RELX | 1.23% | 51.615 | $ | |
NGG | 5.26% | 69.43 | $ | |
VOD | 2.67% | 9.37 | $ | |
BCE | 2.63% | 22.41 | $ | |
JRI | -1.56% | 12.84 | $ | |
BP | -7.28% | 31.515 | $ | |
BCC | -7.62% | 94.84 | $ | |
CMSD | -0.73% | 22.665 | $ |

'Remarkable global progress': HIV cases and deaths declining
The number of new HIV infections and deaths has fallen across the world, marking significant progress in the fight against the disease.
But HIV is far from being stamped out, health experts warn ahead of World AIDS Day on Sunday.
- Uneven progress -
During the 2010s, the number of HIV infections across the world declined by a fifth, according to a major study published in The Lancet HIV journal on Tuesday.
Deaths related to HIV, which are generally caused by other diseases during the late stages of AIDS, fell by about 40 percent to below a million a year, the study said.
The decline was mainly driven by improving rates in sub-Saharan Africa, which is by far the hardest-hit region in the global epidemic.
However infections did not go down everywhere. Other regions, such as Eastern Europe and the Middle East, saw HIV numbers increase.
And the world remains far from the United Nations target of virtually eradicating AIDS-related deaths by 2030, the researchers said.
"The world has made remarkable global progress to significantly reduce the number of new HIV infections," said lead study author Hmwe Kyu of the US-based Institute For Health Metrics and Evaluation.
"More than a million people acquire a new HIV infection each year and, of the 40 million people living with HIV, a quarter are not receiving treatment," she said in a statement.
- Effective tools -
Preventative treatments called Pre-Exposure Prophylaxis (PrEP) have proven to be a powerful tool in the fight against HIV.
These daily pills reduce the risk of getting HIV from sex by around 99 percent.
They have helped drive down HIV rates in many countries. In some, such as France, health authorities are urging PrEP to be made more available to more people, rather than just men who have sex with men.
"It is something that can be used by anyone who needs it at some point in their sexual life," French infectious disease specialist Pierre Delobel told a press conference.
For people who have been infected with HIV, antiretroviral therapy can reduce the amount of the virus in their blood to undetectable levels.
An undetectable viral load means that there is less than a one percent chance that breastfeeding mothers pass HIV onto their babies, according to the US Centers for Disease Control and Prevention.
- New drug raises hopes -
These tools have worked well in wealthier countries but the high costs have meant that poorer countries -- such as in Africa -- have often been left behind.
There are fears that this history could repeat for a new drug that has been hailed as a potential game-changer in the battle against HIV.
Early trials have found that the antiretroviral treatment lenacapavir is 100 percent effective in preventing HIV infection. And it only needs to be injected twice a year, making the drug far easier to administer than current regimens requiring daily pills.
US pharmaceutical giant Gilead has been charging around $40,000 per person per a year for the treatment in several countries.
But researchers have estimated the drug could be made for as little as $40, calling on Gilead to allow for cheaper access in hard-hit nations.
Last month, Gilead announced it had signed licensing deals with six generic drugmakers to produce and sell lenacapavir in lower-income countries.
While experts largely welcomed the move, some noted that millions of people with HIV live in countries not included in the deal.
The twice-yearly injection is also hoped to help get around another problem for administering HIV drugs -- the stigma that comes along with having the disease.
- What about a vaccine? -
Despite decades of effort, a vaccine for HIV remains elusive.
But the lenacapavir shot is "like having a vaccine basically", Andrew Hill, a researcher at the UK's Liverpool University, told AFP earlier this year.
A handful of patients have also been effectively cured of HIV.
But these cures happen only after a patient endures a brutal stem cell transplant for their leukaemia, so is not an option for almost all people living with HIV.
F.Dubois--AMWN